Principal Financial Group Inc Cardiff Oncology, Inc. Transaction History

Principal Financial Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$1.17 - $2.61 $63,988 - $142,743	-54,691 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$2.11 - $7.25 $54,049 - $185,716	-25,616 Reduced 31.9%	54,691 $136,000
Q4 2021 Feb 09, 2022	SELL	$5.18 - $7.24 $347,236 - $485,326	-67,034 Reduced 45.5%	80,307 $483,000
Q3 2021 Nov 09, 2021	SELL	$5.01 - $7.58 $11,177 - $16,910	-2,231 Reduced 1.49%	147,341 $981,000
Q2 2021 Aug 10, 2021	BUY	$6.65 - $10.04 $994,653 - $1.5 Million	149,572 New	149,572 $994,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $107M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.